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Abstract
Purpose This retrospective single-institution cohort study
aims to evaluate if therapeutic approach, tumour site,
tumour stage, BMI, gender, age and civil status predict
body weight loss and to establish the association between
weight loss on postoperative infections and mortality.
Methods Consecutive patients with head and neck cancer
were seen for nutritional control at a nurse-led outpatient
clinic and followed-up for 2 years after radiotherapy.
Demographic, disease-specific and nutrition data were col-
lected from case records. The primary outcome measure was
maximum body weight loss during the whole study period.
Results Thenadirofbodyweightlosswasobserved6months
after radiotherapy. In total, 92 patients of 157 (59%) with no
evidence of residual tumour after treatment received enteral
nutrition. The mean maximum weight loss for patients
receiving enteral nutrition and per oral feeding was 13% and
6%, respectively (p<0.001). Using multivariate analysis,
tumour stage (p<0.001) was the only independent factor of
maximum weight loss. Weight loss was not significantly
related to risk for postoperative infection.
Conclusions Weight loss is frequently noted among head and
neck cancer patients during and after treatment. Weight loss
was not found to be associated with postoperative infections
and mortality. Nutritional surveillance is important in all
patients, but special attention should be given to those on
enteral nutrition and those with more advanced disease.
Keywords Head and neck cancer.Radiotherapy.Enteral
nutrition.Body weight loss.Nutrition.Postoperative
infections
Introduction
In the treatment of patients with head and neck (H and N)
cancer, nutritional issues have been raised and discussed for
decades. The tumour itself, radiation-induced fibrosis and
surgical defects are reported to be followed by excessive
weight loss and malnutrition [1, 2]. Problems include
dysphagia, xerostomia, mucositis, loss of appetite, smell
and taste changes, as well as pain and badly fitted dentures
[3–5]. Long-term malnutrition is one of the reported
sequelae of H and N cancer, possibly related to muscle
loss, cachexia and psychological and emotional distress [2,
4]. Greater weight loss during radiotherapy (RT) has been
associated with postsurgical infections and wound healing
problems [6–8]. Weight loss has also been found to be
related to increased mortality in H and N cancer patients
[6], but the issue is controversial and debated. It is
important to be aware of the fact that nutritional problems
are often already present before treatment, which is
probably related to the tumour site [9], and that negative
lifestyle factors may precede cancer diagnosis [10].
The nutritional management of patients with H and N
cancer is very complex because several factors are
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and other individual factors. Some studies have reported
that cancer patients may benefit from early identification
and treatment of poor nutritional status [11, 12]. Regular
measurements of body weight during and after treatment of
H and N cancer have been identified as an important and
cheap method to use for surveillance [13]. In addition, body
mass index (BMI) has been suggested as one important
indicator, especially in patients receiving RT [14].
The management of prevention and treatment for weight
loss is an area of great interest, but a golden standard is still
not available. Some authors suggest that the indication for
enteral nutritional treatment is weight loss greater than 5%
of the patients' initial weight, whereas others advocate that
enteral therapy should begin before RT treatment [15, 16].
In most cases, enteral tube feeding is the method of choice
for nutritional treatment in H and N cancer patients with
swallowing problems because the majority of such patients
have normal gastrointestinal absorption [5]. The two most
common ways for enteral administration is via a polyure-
thane nasogastric feeding tube (NGT) or a percutaneous
endoscopic gastrostomy (PEG) tube.
A number of factors influence the long-term effects of
RT and surgery on body weight loss in H and N cancer
patients. However, these factors, including how much body
weight patients actually lose, how weight loss affects the
risk for postoperative infection, as well as morbidity and
mortality, have not been thoroughly and systematically
investigated. This study is utilising information from a
database with records from a structured nutritional surveil-
lance programme offered to H and N cancer outpatients and
led by registered nurses. The purposes of this study were
(1) to evaluate if therapeutic approach, tumour site, tumour
stage, BMI, gender, age and civil status predict body weight
loss and (2) to examine the association between weight loss
on postoperative infections and mortality in a cohort of H
and N cancer patients during RT and up to 2 years after
termination of RT.
Patients and methods
Sample
During 2000–2004, 232 consecutive outpatients with H and
N cancer were offered nutritional follow-up at a nurse-led
outpatient clinic before RT. The patients were diagnosed
and treated at the Departments of ENT and Oncology,
Karolinska University Hospital, Stockholm, Sweden. Forty-
eight patients were neither motivated nor did they attend the
nurse-led outpatient clinic for nutritional follow-ups, three
died at the beginning of the treatment, two patients were
initially planned for preoperative radiotherapy but under-
went surgery and postoperative RT and one was excluded
because of an initial incorrect diagnosis. The present
retrospective study includes the remaining sample of 178
(77%) patients with H and N cancer that agreed to
participate in the nutritional follow-ups.
Treatment
Histological specimens of H and N cancer were obtained by
endoscopic examination under general anaesthesia. The
treatment modality was presented to the patient at a weekly
multiprofessional team conference. Treatment consisted of
either external beam RT (EBRT) as a single modality
treatment or preoperative EBRT followed by surgical
excision. The protocol included assessment of therapeutic
response using clinical examination or endoscopic control
under general anaesthesia about 4 weeks after EBRT.
Surgery was generally performed 4 to 6 weeks after
termination of EBRT.
Structured nutritional surveillance programme
The patients were followed from the first initial visit at the
ENT clinic before treatment. Before treatment, a dietician
offered all patients dietary counselling, giving advice about
high-caloric diet, and when needed, patients were offered
nutritional supplements. The patients' body weight was
regularly assessed using two identical waves (patients did
not have shoes and outdoor clothing when weighed). Patients
with dysphagia and weight loss of >5% of their initial body
weight (defined as the weight taken at the initial diagnostic
endoscopy) and patients with expected nutritional problems
that were caused by advanced tumour (stage IV) were
offered enteral nutrition (EN) using a NGT or PEG.
Data collection
All data were collected from nursing and medical records.
Data were collected from the first clinical visit and up to
2 years after RT.
Demographic and disease-specific data
Demographic data collected were age, gender and civil
status. Disease-specific data were diagnosis, TNM classifi-
cation and tumour stage, date and treatment plan decided at
the weekly multiprofessional team conference, start and end
of RT, type of RT, brachytherapy, RT dose given in Grays
(Gy), result of RT, major surgery or not, date and type of
surgery, patho-anatomical diagnosis (PAD), postoperative
infection requiring intravenous or per oral antibiotic
treatment (i.e. wound infection, pneumonia or urinary tract
infection), recurrence (including cancer progress during RT,
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and deceased within 2 years.
Nutritional data
BMIwascalculatedwiththefollowingformula:kg/m².BMI1
ranges from underweight, <20 if <70 years old; if >70 years
old, <22; BMI 2=normal weight >20/22–24.9; BMI 3=
overweight, 25.0–29.9 and BMI 4=obese, 30.0 and above for
sickadults[17]. Body weight: at initial diagnostic endoscopy,
at start of RT, after 2 weeks of RT, after 4 weeks of RT, at
end of RT, 1 month after RT termination, at the time of
surgery, 6 months after termination of RT and 1 to 2 years
after RT. Nutritional support: EN or no EN and when
nutritional support was given to the patient in relation to the
treatment (before, during or after RT).
Statistical analyses
The lowest registered body weight during the whole study
period was compared with the first registered pre-treatment
body weight and defined as the maximum weight loss
expressed in per cent. Data were analysed with regard to
treatment, either single modality radiotherapy (RT group) or
combined treatment (RT and surgery group). To analyse
variances of groups, unpaired t test or one-way ANOVA
was used. To analyse the relationship between variables,
linear regression was applied to predict maximum weight
loss. The variables used in the linear regression analysis
were tumour stage (1=I, 2=II, 3=III and 4=IIII), tumour
site (1=larynx, 2=oropharynx or oral cavity), surgery (1=
no and 2=yes), gender (1=men and 2=woman) and age
(numerical). The study is a retrospective explorative study,
and to answer the main objectives regarding predictors of
weight loss and the association between weight loss and
postoperative infections, the sub-groups of patients were
found to be too small and thereby rendering lack of
statistical power. However, to detect a significant difference
of alpha <0.05 with a power of 0.80 in weight loss between
patients receiving EN and those not receiving EN, 49
patients in each group were demonstrated to be enough.
Statistical analyses were carried out using GraphPad Prism
and SPSS. A p<0.05 was considered significant. The study
was reviewed and approved by the Regional Ethical Board
in Stockholm (2005/48-31).
Results
Descriptive data
Table 1 presents the characteristics of the 178 patients (mean
age of 60.4 years; range, 29–85 years). The three largest sub-
groups were patients with oropharyngeal cancer (n=73), of
which 79% received combined modality treatment, patients
with cancer in the oral cavity (n=42) and patients with
laryngeal cancer (n=37), where 79% and 32%, respectively,
received combined modality treatment. To study the differ-
ence in weight loss between single modality RT and
combined treatment (preoperative RT and surgery), the
cohort was stratified according to therapeutic approach. In
Table 2, treatment and response for patients receiving RT as
single modality treatment (n=60) are presented. The thera-
peutic result was controlled with either clinical evaluation
(28 patients, 47%) or endoscopic control (32 patients, 53%).
Fifty-two patients (87%) showed a clinical complete re-
sponse and constituted the RT group. Table 3 shows
treatment and response for patients receiving combined
modality treatment (n=118). Seventy patients (59%) under-
went neck dissection, 15 patients (13%) underwent resection
of the primary tumour and 33 patients (28%) underwent
resection of the primary tumour and neck dissection with or
without reconstruction. Altogether, 105 patients (89%) had
radical surgery or no evidence of microscopic tumour after
RT and thereby constituted the RT and surgery group.
Weight loss and enteral nutrition
Weight loss during the observation period
Information about the patients' weight and nutritional
situation for the two groups is presented in Table 4,s h o w i n g
a nadir of mean body weight 6 months after RT. Twelve
patients in the RT group (23%) and 4 patients in the RT and
surgery group (4%) retained or gained weight, 11 (21%) and
16 (15%) patients lost <5% of their initial body weight, 9
(17%) and 29 (28%) patients lost between 5% and 10%, 16
(31%) and 44 (42%) patients lost >10% and <20% and 4
(8%) and 12 (11%) patients lost ≥20%, respectively. Of the
latter 16 patients with maximum weight loss of ≥20%, 9 had
oropharyngeal cancer (stage III=2 patients, stage IV=7
patients), 2 had cancer in the oral cavity (stage II=2
patients), 2 had hypopharyngeal cancer (stage IV=2
patients), 1 had laryngeal cancer (stage IV=1 patients), 1
had nasopharyngeal cancer (stage III=1 patient) and 1 had
an unknown primary with cervical lymph node metastasis.
The mean BMI at the time of diagnosis was, for the RT
group, 24.9 (SD, 4.7; range, 17–39) and for the RT and
surgery group, 25.4 (SD, 3.8; range, 17–37). There was no
difference in maximum weight loss between the four BMI
groups(BMIcalculatedfromthe first registeredweight) in the
RTgroup.ThemeanmaximumbodyweightlosswasforBMI
1, 5%; BMI 2, 9%; BMI 3, 6% and BMI 4, 10%. However, in
the RT and surgery group, a significant difference was
observed (p<0.05). Mean maximum body weight loss was
for BMI 1, 7%; BMI 2, 9%; BMI 3, 13% and BMI 4, 12%.
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Altogether, 141 out of 157 patients (90%) were still alive at
the 1- to 2-year follow-up period. Of these patients, 122
were considered tumour free, and weight was registered in
81 (66%) of them. The mean body weight loss was 7.5%
between the initial weight and the weight taken at the 1- to
2-year follow-up and did not significantly (p=0.06) differ
from the mean body weight loss 6 months after RT (10%).
The corresponding figures for the patients with recurrence
(the weight registered in 13 of 19 patients, i.e. 68%) were
non-significant (p=0.89) (7% and 8%, respectively).
Enteral nutrition
In the RT group, 21 out of 52 patients (40%) and in the
RT and surgery group, 71 out of 105 patients (68%)
received EN. Three of them started EN before, 62 during
and 27 after termination of RT. Characteristics of patients
receiving EN and patients that did not receive EN are
shown in Table 5. The mean maximum body weight loss
for patients receiving EN (n=92) and per oral feeding (n=
65) was 13% and 6%, respectively, showing a significant
difference (p<0.001).
Characteristics Number of patients (%)
All patients Radiotherapy
group
Radiotherapy and
surgery group
n=178 n=60 n=118
Gender
Male 125 (70) 42 (70) 83 (70)
Female 53 (30) 18 (30) 35 (30)
Marital status
Married, cohabiting 120 (67) 39 (65) 81 (69)
Living aloneª 58 (33) 21 (35) 37 (31)
Diagnosis
Oropharynx 73 (41) 15 (25) 58 (49)
Oral cavity 42 (24) 9 (15) 33 (28)
Larynx 37 (21) 25 (42) 12 (10)
Hypopharynx 11 (6) 6 (10) 5 (4)
Nasopharynx 6 (3) 4 (7) 2 (2)
Cancer at two sites 4 (2) 1 (2) 3 (3)
Unknown primary 3 (2) 0 3 (3)
Others
b 2 (1) 0 2 (2)
Tumour stage (I–IV)
I 21 (12) 17 (28) 4 (3)
II 33 (18) 19 (32) 14 (12)
III 43 (24) 12 (20) 31 (26)
IV 76 (43) 12 (20) 64 (54)
No stage 3 (2) 0 3 (3)
Information missing 2 (1) 0 2 (2)
Table 1 Demographic and dis-
ease details of patients with head
and neck cancer at the nurse-led
outpatient clinic
ªSingle, divorced, widowed or
people in a relationship but not
living together
b Basalioma and squamous cell
carcinoma in the parotid gland
and temple region
Table 2 Treatment and response for the RT group (patients with head
and neck cancer receiving radiotherapy as a single modality treatment,
n=60)
Treatment and response Number of patients (%)
Radiotherapy (EBRT, BT)
Conventional EBRT 52 (87)
Conventional EBRT+BT 6 (10)
Hyperfractionated EBRT 2 (3)
Dose given in Grays to the primary tumour
70 Gy 1 (2)
68 Gy 11 (18)
64 Gy 34 (57)
54 Gy 1 (2)
50 Gy 3 (5)
Information missing 10 (17)
Response after radiotherapy as single modality
treatment
Complete response 52 (87)
Partial or no response 8 (13)
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patients that had registered weight 1 to 2 years after
termination of treatment, 60 (64%) had received EN and 34
(36%) had received per oral feeding. Patients that had
received EN had lost significantly more weight (10%) than
patients with oral feeding (3%) at the 1- to 2-year follow-up
period (p<0.001).
Importance of weight loss for postoperative infection
and mortality
Postoperative infections
Thirty-four of the 105 patients (32%) in the RT and surgery
group had a postoperative infection. No significant differ-
ence was found between the mean preoperative weight loss
in patients with postoperative infection (7%) and patients
without postoperative infection (6%).
Deceased patients
Within 2 years after RT, 29 patients died; the mean
maximum weight loss of these patients was 9%, which
can be compared with 10% for the 128 patients that were
still alive. No significant difference in maximum body
weight loss was found between the two groups.
Table 4 Comparison of nutritional situation between the RT group (n=52) and the RT and surgery group (n=105) without evidence of residual
tumour after treatment in the sample of head and neck cancer patients followed-up at a nurse-led outpatient clinic
Nutritional characteristic Radiotherapy group Radiotherapy and
surgery group
BMI (kg/m²) at time of diagnosis, n (%)]
1. Underweight (<70 years=<20, >70 years=<22) 8 (15) 10 (10)
2. Normal weight (>20/>22–24.9) 19 (37) 41 (39)
3. Overweight (25.0–29.9) 17 (33) 38 (36)
4. Obese (>30.0) 8 (15) 16 (15)
Body weight in kg, mean±SD (n)
At initial diagnostic endoscopy 73.7±15.2 (46) 77.7±14.9 (99) p value
At start of radiotherapy 75.2±1.53 (38) 79.1±15.4 (90) 0.142ª
After 2 weeks of radiotherapy 74.8±14.9 (45) 77.6±14.9 (91) 0.025
After 4 weeks of radiotherapy 72.4±14.5 (41) 76.4±14.4 (91) 0.003
At end of radiotherapy 72.0±15.3 (42) 74.5±14.3 (96) 0.006
1 month after radiotherapy 71.7±14.9 (38) 73.1±13.7 (93) 0.009
6 months after radiotherapy 65.9±14.4 (30) 69.3±12.1 (68) 0.051
1–2 years after radiotherapy 70.7±13.6 (25) 69.9±12.8 (62) 0.244
Nutrition supplement, n (%) 0.002
b
No 31 (60) 34 (32)
Enteral nutrition 21 (40) 71 (68)
ªComparison of per cent body weight change between the two groups
bComparison between the groups (Fisher's exact test)
Table 3 Treatment and response for RT and surgery group (patients
with head and neck cancer receiving preoperative radiotherapy and
surgery, n=118)
Treatment and response Number of patients (%)
Radiotherapy (EBRT, BT)
Conventional EBRT 97 (82)
Conventional EBRT+BT 4 (3)
Hyperfractionated EBRT 16 (14)
Hyperfractionated EBRT+BT 1 (1)
Dose given in Grays to the primary tumour
68 Gy 35 (30)
66 Gy 2 (2)
65 Gy 1 (1)
64 Gy 59 (50)
54 Gy 1 (1)
50 Gy 8 (7)
Information missing 12 (10)
Response after preoperative radiotherapy
and surgery PAD result
Radical surgery or no evidence
of microscopic tumour
105 (89)
Non-radical marginsormarginstatus unclear 13 (11)
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There were no significant differences in maximum body
weight loss between gender, different age groups (29–49,
50–59, 60–69 and 70–85 years old) and civil status
(married/cohabiting and living alone). When the groups
diagnosed with cancer in the oropharynx, oral cavity or
larynx were compared, there was a significant difference in
maximum body weight loss (p<0.001). The mean body
weight loss for patients with cancer of the oropharynx was
11%, for patients with cancer of the oral cavity, 10%, and
for patients with cancer of the larynx, 5%. There was also a
significant difference for the whole sample when comparing
the different tumour stages, I to IV (p<0.0001). The mean
maximum body weight loss for patients with stages I, II, III
and IV was 3%, 9%, 10% and 12%, respectively. The mean
maximum body weight loss in patients that underwent
combined treatment with EBRT and surgery was 11% and
was significantly higher than in patients that received only
EBRT (7%, p<0.005).
Linear regression analysis was done with maximum body
weight loss as the dependent variable. The independent
variables were tumour stage, tumour site, surgery, gender
and age. The linear regression analysis showed that only
tumour stage was significantly predictive of maximum body
weight loss (Table 6). In total, the model explained 19.7% of
the variance.
Discussion
This is a unique material from a nurse-led outpatient clinic
for nutritional control of H and N cancer patients. At
diagnosis, all patients received nutritional counselling and
were informed that a high-caloric intake was important in
order to avoid weight loss during RT. The patients in
general gained weight before the start of RT. Thereafter,
the mean weight decreased gradually, reaching a nadir at
about 6 months after RT. Patients receiving combined
modality treatment had significantly greater maximum
weight loss as well as greater weight loss after RT in
connection to surgery.
By using nutritional intervention on patients undergo-
ing RT, Isenring et al. [18] showed an improved dietary
intake both in energy and protein compared with standard
practice. There was also an indication of weight loss in the
Enteral nutrition RT group RT and surgery group
Characteristics Yes No Yes No
Gender
Male 13 24 53 20
Female 8 7 18 14
Pre-treatment BMI (kg/m²)
1. Underweight (<70 years=<20, >70 years=<22) 4 4 6 4
2. Normal weight (>20/>22–24.9) 8 11 26 16
3. Overweight (25.0–29.9) 5 12 29 9
4. Obese (>30.0) 4 4 10 5
Diagnosis
Oropharynx 7 5 33 23
Oral cavity 2 5 21 7
Larynx 8 17 7 2
Hypopharynx 3 2 5 0
Nasopharynx 1 2 2 0
Cancer at two sites 0 0 0 1
Unknown primary 0 0 2 1
Othersª 0 0 1 0
Tumour stage (I–IV)
I3 1 4 0 3
II 8 11 7 2
III 5 4 17 11
IV 5 2 43 17
No stage 0 0 2 1
Information missing 0 0 2 0
Table 5 Characteristics of the
two groups of patients with head
and neck cancerreceiving and not
receiving enteral nutrition: RT
group (patients receiving radio-
therapy as a single modality
treatment and clinical complete
response, n=52) and RTand
surgery group (patients receiving
preoperative radiotherapy and
surgery with radical surgery or
no evidence of microscopic
tumour, n=105)
ªBasalioma and squamous cell
carcinoma in the parotid gland
and temple region
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mised trial, Lee et al. [19] demonstrated the efficacy of
nutritional support. Patients receiving follow-up by a
special programme that included nutritional counselling
and nutritional support had significantly less weight loss
compared with a group that did not get such help. It has
also been shown that patients receiving EN with an
enriched formula had less local wound complications [8].
In our study, a dietician gave all patients nutritional
counselling, but the guidelines for tube feeding were based
mainly on a wait-and-see procedure in which patients with
swallowing problems and loss of >5% of their pre-treatment
weight were offered EN through the use of a NGT or PEG.
Another established indication for EN was patients with
expected nutritional problems caused by advanced tumour
(stageIV).Itshouldbeemphasisedthattheliteratureoffersno
clear consensus of the optimal method for nutritional
management in H and N cancer patients [20]. Some authors
recommend elective PEG to all patients before treatment.
However, the potential benefit from a wait-and-see proce-
dure with PEG insertion is supported by the findings of
complications and prolonged dysphagia in patients receiving
PEG [15, 21, 22]. In our study, 87% of patients receiving
single modality RT and 89% of patients who underwent
combined treatment were considered tumour free after
treatment; of these, 56% and 81%, respectively, had a
maximum weight loss of more than 5%. A total of 59%
received EN. Enteral feeding could not restore weight loss,
and patients given tube feeding lost significantly more body
weight compared with the group that could maintain
adequate oral feeding. This finding is in agreement with
results from Nguyen et al. [23] who reported that 98% of
104 H and N cancer patients receiving a PEG before
chemoradiation treatment lost weight despite enteral feeding
and nutritional assessment from a dietician.
Malnutrition, which is multifactorial in origin, is reported
tobeapotentialsourceofincreasedmorbidityandmortalityin
H and N cancer patients [24]. Therefore, optimising nutrition
is thought to improve the outcome of treatment as well as
affect survival rate. In our study, the clinical significance of
moderate weight loss was found to be of modest importance
during both treatment and rehabilitation periods. Moreover,
8% and 11% in the RT group and RT and surgery group,
respectively, lost ≥20% in weight during the follow-up
period. Weight loss was not identified as a risk factor for
postoperative infection.
Reduced dietary intake and increased energy expenditure
are two main attributes to describe loss of body weight [10].
Deterioration of physical function and performance has
been observed when treating H and N cancer patients with
chemoradiation. Such deterioration is thought to be due to
abnormal changes in metabolism, body composition and
the inflammatory state [25]. In the present unselected H and
N cancer patient cohort, univariate analysis revealed that
therapeutic approach, tumour site and tumour stage were
correlated to maximum weight loss. Patients received
treatment appropriate for tumour site and stage. Consider-
ing this aspect, patients with cancer in the oral cavity or
oropharynx and patients receiving combined treatment
modality showed the greatest weight loss. However, in the
multivariate analysis, the only prognostic predictor was
tumour stage. The results are commensurate with findings
in a study on H and N cancer patients with stages I and II
during EBRT, where tumour site and stage were found to be
associated with weight loss [26]. Overall, we found that
weight loss did not influence the therapeutic results 1–
2 years after termination of treatment. This finding is
contrary to that of Pedruzzi et al. [27]. In their study of
patients with cancer in the oropharynx, weight loss was
shown to be a significant predictor of treatment response
for survival.
The WHO recommendation to consider a patient
underweight is a BMI <18.5 kg/m². In a study by Isenring
et al. [28] of 50 cancer patients prior to RT, only 3 of 50
(6%) were classified underweight with a BMI <18.5 kg/m²,
which indicates some limitations in using the WHO
classification for cancer patients. In our study, we define
underweight as a BMI <20 kg/m² in patients <70 years old,
and in patients >70 years old, <22 kg/m², in accordance
with the Swedish national recommendations for severely
sick people [17]. According to this classification, 18 of
157 patients (11%) in our study were classified as
underweight before treatment. Hence, by using this wider
range to find patients who are at significant risk for
malnutrition, a higher number of patients were identified
at the time of diagnosis. Only 8 of the 157 patients (5%)
would have been classified as underweight if the
classification >18.5 kg/m² had been used in the present
Table 6 Linear regression analysis in head and neck cancer patients
(n=157) with maximum weight loss in per cent as the dependent
variable
Independent variables Standardised beta
coefficients
p value
Tumour stage 0.379 0.000
Diagnosis 0.152 0.124
Surgery −0.099 0.341
Gender 0.093 0.243
Age −0.028 0.738
R²=0.197
Explanation of independent variables: tumour stage (1=I, 2=II, 3=III
and 4=IIII), diagnosis (1=larynx, 2=oropharynx or oral cavity),
surgery (1=no and 2=yes), gender (1=men and 2=woman) and age
(numerical)
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underweight before the start of treatment, a low BMI was
not found to be a risk factor for weight loss in patients
that received RT and surgery.
In the present study, there was a trend for partial recovery
of mean body weight for tumour-free patients 1–2 years after
termination of RT. At this time of observation, the group of
patients receiving enteral feeding still had significantly lost
more body weight than the group of patients that could
maintain oral feeding. One interpretation of this finding is
that enteral feeding as a method to reduce weight loss is not
completely successful. This lack of success could depend on
a number of factors but nevertheless indicate that patients
receiving EN could properly benefit the most from regular
follow-ups in a longer perspective after treatment.
The main limitation ofthe current study isthe retrospective
and explorative design that does not make it possible to
perform adequate power analysis which restricts generaliza-
tion. However, this is a unique database of a cohort
systematically followed-up with regard to weight loss during
a long time after treatment. Together with that, H and N
cancer patients constitute a small and vulnerable group
which is often difficult to follow for a longer period of
time the results of the study should not be diminished.
The results might be of guidance both in clinical practice
and for further studies. The optimal study for studying
the value of nutritional surveillance would be to compare
a study group with a control group. However, one might
discuss the ethical dilemma to provide nutritional support
to one group and not to another group of patients,
considering that nutritional surveillance is seen as crucial
during the treatment phase of patients with H and N
cancer. Another limitation of our retrospective design is
that it is not possible to perform a more thorough analysis
of the effect of EN. It has generally been accepted that
nutritional support and supplements are doing more good
than harm in H and N cancer patients. Benefits from
nutritional support, however, have been under debate in
recent years. Moreover, one should keep in mind the
theoretical risk that recurrence of malignancy and survival
rate in the long run might be negatively affected by
nutritional support. A study by Rabinovitch et al. [29]o f
1,073 H and N cancer patients demonstrated poorer 5-
year locoregional control and survival rate for patients
that received nutritional support before treatment com-
pared with patients who received nutritional support
during treatment and patients who did not. However,
the present findings do not lend support for a changed
attitude toward the value of nutritional support in H and
N cancer patients receiving RT or combined treatment.
More studies on nutritional surveillance programmes
with longer follow-up need to be carried out. Nutritional
management of H and N cancer is still an important part
of care to support patients during and after treatment,
irrespective of less obvious effects on survival and
infection prevention.
Conclusions
H and N cancer patients were found to lose weight after
treatment, even though they received a nutritional surveil-
lance programme of regular follow-ups up to 2 years after
determination of treatment. The nadir of body weight was
observed about 6 months after completion of RT. A
significantly greater maximum weight loss was seen in
patients undergoing combined modality treatment; a
majority of them (68%) received EN, and it seemed as
though this treatment could not prevent weight loss. The
strongest prognostic predictor for maximum weight loss
was tumour stage. Nutritional surveillance is important for
all patients, especially in patients with a more severe
disease stage or that need EN.
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